Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference

LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that Bruce Steel, Equillium’s chief executive officer, will present at the H.C. Wainwright Virtual BioConnect Conference. The presentation will be available on January 10, 2022, at 7:00 am EST.

The presentation will provide a high-level overview of itolizumab’s mechanism of action followed by topline data from the company’s Phase 1b EQUATE study in acute graft-versus-host disease (aGVHD), regulatory feedback leading directly to a pivotal study in aGVHD, and the EQUALISE study in systemic lupus erythematosus and lupus nephritis. Members of Equillium’s leadership team will be available for one-on-one meetings during the conference.

A webcast of the presentation will be available under the “Investors” section of the Company’s website at https://www.equilliumbio.com/investors/events-and-presentations/default.aspx for 90 days.

About Equillium
Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus/lupus nephritis and uncontrolled asthma.

For more information, visit www.equilliumbio.com.